Home / Market News / $VTRS

$VTRS news and market catalysts

The 23 most recent market catalysts affecting $VTRS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

23 catalysts 6 high impact 17 bullish 1 bearish Pharmaceuticals
Nov 18, 2026 Corporate Catalyst Bullish Impact 55
Oppenheimer Adjusts Price Target on Viatris to $26
Oppenheimer updated its outlook on Viatris Inc., raising its price target from $25 to $26 and reaffirming its Outperform rating. This action indicates that the analyst firm sees sl…
Nov 17, 2026 Corporate Catalyst Bullish Impact 95
Viatris Completes Acquisition of Pacira BioSciences
Viatris Inc. has officially completed its acquisition of Pacira BioSciences for $36.50 per share in cash. This transaction is a significant strategic move for Viatris, as it direct…
Nov 17, 2026 Corporate Catalyst Neutral Impact 90
Viatris Inc. Completes Acquisition of Pacira BioSciences
Viatris Inc. announced the completion of its acquisition of Pacira BioSciences, a specialty pharmaceutical company known for its non-opioid pain management solutions like EXPAREL. …
Nov 16, 2026 Corporate Catalyst Bullish Impact 55
Viatris Announces Multiyear Partnership with Cadillac Formula 1 Team
Viatris has entered into a multiyear partnership with the Cadillac Formula 1 Team, positioning itself as the Official Global Pharmaceutical Partner from 2027. This move is signific…
Nov 16, 2026 Corporate Catalyst Bullish Impact 55
Cadillac Formula 1 Team Announces Multiyear Partnership with Viatris
The Cadillac Formula 1 Team, backed by General Motors, has secured a multiyear sponsorship deal with Viatris Inc., effective 2027. This partnership is a positive development for bo…
Nov 13, 2026 Corporate Catalyst Bullish Impact 55
Barclays Adjusts Price Target on Viatris to $25 From $22, Keeps Overweight Rating
Barclays updated its outlook on Viatris Inc., raising the price target to $25 from $22 and reaffirming its Overweight rating. This action signals increased confidence from a major …
Nov 6, 2026 Corporate Catalyst Bullish Impact 55
UBS Adjusts Viatris Price Target to $28 From $26, Maintains Buy Rating
UBS adjusted its price target for Viatris (VTRS) to $28 from $26 and maintained its Buy rating after the company's Q3 2026 earnings report. This analyst action indicates that UBS l…
Nov 6, 2026 Corporate Catalyst Bullish Impact 55
Jefferies Adjusts Viatris Price Target
Jefferies raised its price target for Viatris to $22 from $20 after the company's Q3 2026 earnings report. This analyst action indicates that Jefferies sees improved value or perfo…
Nov 5, 2026 Corporate Catalyst Bullish Impact 75
Viatris Reports Q3 2026 Financial Results and Raises 2026 Guidance
Viatris reported a net loss of $325.3 million for Q3 2026, a significant increase from the $128.2 million loss in the same period last year. Despite this, the company raised its fu…
Oct 28, 2026 Corporate Catalyst Bullish Impact 55
Viatris Addresses Supply Demand for Estradiol Products
Viatris has experienced a substantial increase in demand for its estradiol products, leading the company to significantly ramp up production. This proactive measure, including 24/7…
Oct 21, 2026 Corporate Catalyst Bullish Impact 55
JPMorgan Adjusts Viatris Price Target to $20
JPMorgan Chase adjusted its price target for Viatris (VTRS) upwards from $18 to $20. While this represents a positive revision in the analyst's valuation, the firm simultaneously m…
Oct 16, 2026 Corporate Catalyst Bullish Impact 65
Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia In Adults
Viatris received FDA approval for RYZUMVI to treat presbyopia in adults, significantly expanding the drug's potential market beyond its current use for pharmacologically-induced my…
Oct 8, 2026 Corporate Catalyst Bullish Impact 95
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Viatris is acquiring Pacira BioSciences for $1.65 billion, paying $36.50 per share in cash. This move is a significant strategic shift for Viatris, aiming to bolster its innovative…
Oct 8, 2026 Corporate Catalyst Neutral Impact 85
Viatris Announces $1.65B Deal To Acquire Pacira BioSciences For $36.50/Share In Cash; Expects Close By End Of 2026
This acquisition represents a significant strategic move for Viatris, aiming to bolster its product pipeline and market presence. For Pacira BioSciences shareholders, the all-cash …
Oct 5, 2026 Corporate Catalyst Bullish Impact 55
UBS Maintains Buy on Viatris, Raises Price Target to $26
UBS analyst Ashwani Verma maintained a 'Buy' rating on Viatris and raised the price target from $23 to $26. This action signals a continued positive sentiment from a prominent fina…
Sep 23, 2026 Corporate Catalyst Neutral Impact 65
Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25
Oppenheimer analyst Les Sulewski has initiated coverage on Viatris (VTRS) with an 'Outperform' rating and a $25 price target. This event is significant because new analyst coverage…
Sep 16, 2026 Corporate Catalyst Bullish Impact 65
Viatris Secures Japan Approval For WAKIX In Treating Excessive Daytime Sleepiness Linked To Sleep Apnea And Narcolepsy
Viatris has received regulatory approval in Japan for WAKIX (pitolisant) to treat excessive daytime sleepiness linked to sleep apnea and narcolepsy. This is a positive development …
Sep 9, 2026 Corporate Catalyst Neutral Impact 65
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20
Leerink Partners' analyst Daniel Clark has initiated coverage on Viatris (VTRS) with an 'Outperform' rating and a $20 price target. This event is significant as new analyst coverag…
Sep 8, 2026 Corporate Catalyst Bullish Impact 55
Argus Research Maintains Buy on Viatris, Raises Price Target to $20
Argus Research analyst Jasper Hellweg maintained a 'Buy' rating on Viatris and raised the price target from $15 to $20. This action signals increased confidence from a reputable re…
Aug 6, 2026 Corporate Catalyst Bearish Impact 75
Viatris shares are trading lower despite reporting better-than-expected Q2 financial results, possibly dragged down by wider GAAP net loss, near-term supply risks, and weakness in Emerging Markets.
This headline highlights a significant corporate catalyst for Viatris. While revenue beat expectations, the market is reacting negatively to underlying issues like a wider GAAP net…
Aug 6, 2026 Corporate Catalyst Bullish Impact 85
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Viatris (VTRS) is undergoing a strategic divestiture of its Tyrvaya asset to Harrow Inc. (HROW) for up to $100 million, allowing Viatris to concentrate on core growth areas like co…
Aug 6, 2026 Corporate Catalyst Bullish Impact 92
Viatris Q2 Adj. EPS $0.69 Beats $0.60 Estimate, Sales $3.756B Beat $3.675B Estimate
Viatris announced Q2 adjusted EPS of $0.69, significantly beating the $0.60 estimate, and sales of $3.756 billion, surpassing the $3.675 billion estimate. This strong financial per…
Jul 14, 2026 Corporate Catalyst Neutral Impact 55
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
This filing provides a curated list of analyst ratings and recent news for three high-dividend healthcare stocks: Viatris, Medtronic, and GSK. For Viatris, two analysts maintained …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.